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Abstract
Background: Exposure of human populations to ambient particulate matter (PM) air pollution significantly contributes to
the mortality attributable to ischemic cardiovascular events. We reported that mice treated with intratracheally instilled PM
develop a prothrombotic state that requires the release of IL-6 by alveolar macrophages. We sought to determine whether
exposure of mice to PM increases the levels of PAI-1, a major regulator of thrombolysis, via a similar or distinct mechanism.
Methods and Principal Findings: Adult, male C57BL/6 and IL-6 knock out (IL-6
2/2) mice were exposed to either
concentrated ambient PM less than 2.5 mm (CAPs) or filtered air 8 hours daily for 3 days or were exposed to either urban
particulate matter or PBS via intratracheal instillation and examined 24 hours later. Exposure to CAPs or urban PM resulted
in the IL-6 dependent activation of coagulation in the lung and systemically. PAI-1 mRNA and protein levels were higher in
the lung and adipose tissue of mice treated with CAPs or PM compared with filtered air or PBS controls. The increase in PAI-
1 was similar in wild-type and IL-6
2/2 mice but was absent in mice treated with etanercept, a TNF-a inhibitor. Treatment
with etanercept did not prevent the PM-induced tendency toward thrombus formation.
Conclusions: Mice exposed to inhaled PM exhibited a TNF-a-dependent increase in PAI-1 and an IL-6-dependent activation
of coagulation. These results suggest that multiple mechanisms link PM-induced lung inflammation with the development
of a prothrombotic state.
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Introduction
There is a well-defined link between acute exposure to ambient
particulate matter (PM) and morbidity and mortality from
ischemic cardiovascular events including acute myocardial infarc-
tion and ischemic stroke [1]. In the past several decades, the
institution of pollution control measures has led to significant
reductions in mean and peak PM levels in most parts of the
developed world [1]. Nevertheless, in more recent population-
based cohorts, investigators have observed a persistent contribu-
tion of PM to mortality from ischemic cardiovascular events [2].
The mechanisms by which PM exposure increases the risk of
ischemic cardiovascular events are incompletely understood.
Several groups of investigators have reported that humans and
rodents exposed to PM develop an enhanced tendency toward
thrombosis and impaired fibrinolysis in the first 24 hours after the
exposure [3,4,5,6,7,8,9]. This time course is consistent with the lag
time of PM-induced mortality reported in population based cohort
studies [1].
Both humans and rodents exposed to PM develop pulmonary
inflammation characterized by bronchoalveolar lavage (BAL) fluid
pleocytosis accompanied by the local and systemic release of
cytokines. Investigators examining the consequences of PM
exposure in humans and rodents have consistently observed an
increase in serum levels of IL-6 or its transcriptional target CRP
[10,11,12,13]. Consistent with these findings, we found that the
release of IL-6 from alveolar macrophages was required for the
development of a prothrombotic state in mice exposed to
intratracheally instilled PM [14]. Following controlled exposures
of men with stable coronary artery disease to diesel exhaust, Mills
et al observed evidence of worsened myocardial ischemia
accompanied by reduced endothelial release of plasminogen
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18525activator [15]. These results suggest that impaired fibrinolysis
might also contribute to the observed increased risk in ischemic
cardiovascular events in PM exposed populations. In this study, we
sought to determine whether: (1) acute PM exposure via inhalation
is sufficient to increase the systemic levels of PAI-1, the major
regulator of fibrinolysis (2) whether exposure to PM via inhalation
activates coagulation through the same mechanism we observed
after exposure to intratracheally instilled PM and (3) whether
similar mechanisms underlie both the induction of PAI-1 and the
activation of coagulation following exposure to PM.
Results
PM2.5 increases white adipose tissue transcription of PAI-1
through a TNF-a-dependent mechanism. We exposed wild-type
and IL-6
2/2 mice to concentrated ambient PM2.5 (CAPs) or
filtered air (FA) 8 hours per day for three days [16]. The mean
daily ambient PM2.5 concentration was 12.763.1 mg/m
3 during
the study period while the mean concentration in the PM exposure
chamber was 88.5613.4 mg/m
3. In mice exposed to CAPs, we
found small but significant elevations in the levels of the pro-
inflammatory cytokines IL-6, MCP-1 and TNF-a in the BAL fluid
(Figure 1A–C). PAI-1 is the major systemic inhibitor of fibrinolysis
and the white adipose tissue is a major site of PAI-1 production,
particularly in response to inflammation [17,18]. We exposed mice
to CAPs 8 hours daily for three days and measured the levels of
PAI-1 mRNA in the white adipose tissue. Compared with mice
concomitantly exposed to filtered air, the CAPs exposed mice had
a significant increase in white adipose tissue PAI-1 mRNA
(Figure 1D). This increase in PAI-1 was similar in both wild-type
and IL-6
2/2 mice (Figure 1D). Canonical signaling through the
TNF-a receptor activates the transcription factor NF-kB, which is
a strong regulator of the PAI-1 promoter [19]. To test the
hypothesis that the increase in PAI-1 transcription observed in
CAPs exposed mice is regulated by TNF-a, we treated mice with
the TNF-a inhibitor, etanercept (10 mg/kg, 3 days before and on
the first day of exposure to CAPs). The administration of
etanercept prevented the increase in white-adipose tissue PAI-1
mRNA in mice exposed to CAPs (Figure 1E).
Exposure to CAPs or instilled urban PM causes the IL-6-
dependent activation of coagulation. Twenty-four hours after the
intratracheal instillation of coarse PM, we reported that mice
develop a prothrombotic state, which requires the release of IL-6
from alveolar macrophages [14]. We sought to determine whether
this pathway is activated upon inhalation of PM2.5. We measured
mRNA levels of IL-6 and its transcriptional targets surfactant
protein B and tissue factor [20] in lung homogenates collected
from mice exposed to CAPs or filtered air for 8 hours daily on
three consecutive days. In wild-type mice, exposure to PM was
associated with an increase in the transcription of IL-6, surfactant
protein B (SFPB) and tissue factor (TF), while the levels of these
transcripts did not increase in contemporaneously exposed
IL-6
2/2 mice (Figure 2A–C). Similarly, we found a significant
increases in the levels of thrombin antithrombin complexes (TAT)
Figure 1. TNF-a is required for the increase in PAI-1 transcription induced by inhalational exposure to CAPs. Wild-type (IL-6
+/+) and IL-
6
2/2 mice were exposed contemporaneously to CAPs (PM2.5) or filtered air (FA) for 8 hours daily on 3 consecutive days and BAL fluid was harvested
at the end of the third day of exposure for measurement of Interleukin-6 (IL-6) (A), Monocyte Chemotactic Protein-1 (MCP-1) (B) and Tumor Necrosis
Factor-a (TNF-a)( C). White adipose tissue was harvested from identically treated mice for measurement of the levels of PAI-1 mRNA (D). Wild type
mice were treated with etanercept (10 mg/kg i.p.) or vehicle (saline) 3 days before and on the first day of exposure to CAPs or FA and white adipose
tissue levels of PAI-1 mRNA were measured after the third day of exposure (E). (*p,0.05 CAPs vs. FA, n$6/group).
doi:10.1371/journal.pone.0018525.g001
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2/2 mice exposed to CAPs
(Figure 2D).
To determine whether the PM-induced changes in coagulation
were similar after exposure to another urban particulate, we
measured BAL fluid IL-6 levels and plasma TAT levels in mice
following the intratracheal administration of urban PM collected
by baghouse from Washington, DC [21]. When we treated wild-
type mice intratracheally with increasing concentrations of this
PM (10 mg, 100 mg and 200 mg), we observed a dose-dependent
increase in the BAL fluid levels of IL-6 (Figure 2E and Figure S1A)
and plasma TAT (Figure 2F and Figure S1B), which were not seen
in IL-6
2/2 mice.
Exposure to urban PM causes the IL-6-dependent
activation of coagulation and deposition of fibrin in the
lung
Acute lung injury is associated with activation of coagulation
and fibrin deposition locally in the lung both in humans and
animals [22,23]. To determine whether PM activates coagulation
in the lung, we treated wild-type mice intratracheally with PM
(200 mg) or PBS and examined lung homogenates for tissue factor
mRNA (qRT-PCR) and protein (immunoblotting) 24 hours later.
Compared to PBS treated mice, PM treated mice had significantly
higher levels of tissue factor protein and mRNA (Figure 3A and
3B). This increase was not evident in IL-6
2/2 mice. In vitro,w e
observed a dose-dependent increase in TF mRNA and protein
expression in a lung epithelial cell line 24 hours after exposure to
PM (Figure S2A and B). To determine whether this activation of
coagulation locally in the lung is sufficient to cause an increase in
fibrin, we measured the BAL fluid levels of fibrin by measuring the
difference in D-dimer before and after treatment of the BAL fluid
with exogenous plasmin as previously described [24]. Wild-type but
not IL-6
2/2 mice treated with intratracheal PM 24 hours earlier
had significantly higher fibrin levels in the lung when compared to
PBS treated animals (Figure 3C). We also observed increased
staining for fibrin/fibrinogen in OCT embedded and snap frozen
lung sections of PM compared with PBS treated mice (Figure S2C).
The IL-6-mediated activation of coagulation is
independent of lung inflammation
We treated wild-type and IL-6
2/2 mice with increasing doses of
PM and measured the severity of the resulting lung injury using a
standardized scoring system [25]. The severity of the lung injury
was similar in wild-type and IL-6
2/2 mice (Figure 4A, B and
Figure S3A, B). The intratracheal instillation of urban PM resulted
in a dose-dependent increase in BAL fluid protein and an increase
in BAL fluid macrophages and neutrophils in both wild-type and
IL-6
2/2 mice (Figure 4C–E and Figure S3C, D).
Exposure to urban PM causes a TNF-a-dependent
increase in PAI-1 in the lung and white adipose tissue
We measured lung PAI-1 mRNA, BAL fluid PAI-1 antigen
levels and white adipose tissue PAI-1 mRNA in wild-type mice
24 hours after the intratracheal instillation of PM (200 mg/mouse)
or PBS. Similar to the results observed in mice exposed to CAPs,
these levels were higher in PM compared with PBS treated mice
Figure 2. Interleukin-6 is required for activation of coagulation after inhalational exposure to concentrated ambient particles
(CAPs) and the instillation of urban PM. Wild-type (IL-6
+/+) and IL-6
2/2 mice were exposed contemporaneously to CAPs (PM2.5) or filtered air
(FA) for 8 hours daily on 3 consecutive days and lung tissue and BAL fluid were harvested at the end of the third day of exposure. Lung levels of
mRNA encoding IL-6 and its transcriptional targets surfactant protein B (SFPB) and tissue factor (TF) (A–C) and plasma levels of thrombin
antithrombin (TAT) complexes (D) were measured. Wild-type (IL-6
+/+) and IL-6
2/2 mice were treated intratracheally with urban PM (200 mg/mouse)
and 24 hours later BAL fluid was obtained for measurement of IL-6 levels (ELISA) (E) and plasma was collected for measurement of thrombin-
antithrombin complexes (F). (*p,0.05 CAPs vs. FA, n$6/group).
doi:10.1371/journal.pone.0018525.g002
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in IL-6
2/2 mice (Figure 5A–C). The PM-induced increases in
TNF-a levels were similar in wild-type and IL-6
2/2 mice
(Figure 5D). Compared to control vehicle (PBS) treated animals,
mice treated with etanercept (10 mg/kg i.p.) 3 days prior to and
on the day of exposure to PM, the PM-induced increase in BAL
fluid levels of PAI-1 (Figure 5E) and PAI-1 mRNA in adipose
tissue (Figure 5F) were significantly reduced.
To determine whether the PM-induced increase in PAI-1
contributed to the increased tendency toward thrombosis induced
by PM exposure, we treated wild type mice with vehicle or
etanercept 3 days before and the day of the administration of
Figure 3. Urban PM induces the IL-6-dependent expression of tissue factor and deposition of fibrin in the lung. Wild-type (IL-6
+/+) and
IL-6
2/2 mice were treated with PM (200 mg/mouse) or PBS for measurement of tissue factor (TF) protein (A) (immunoblotting and densitometry
analysis shown) (n=4/treatment) and mRNA (B) (qRT-PCR) in whole lung homogenates (n=4/treatment). In identically exposed mice, BAL fluid fibrin
was measured as the difference in the levels of D-Dimer pre- and post-digestion with exogenously administered plasmin (C). (*p,0.05, PM vs. PBS,
n=6/treatment).
doi:10.1371/journal.pone.0018525.g003
Figure 4. PM-induced lung injury is similar in wild-type and IL-6
2/2 mice. Wild-type (IL-6
+/+) and IL-6
2/2 mice were treated with PM or PBS
and harvested 24 hours later for histologic evaluation (A). Representative microphotographs of lung sections (hematoxylin and eosin stain, 6100
magnification,6600 (inset) are shown. (B) Assessment of lung injury severity using a 5 point scoring system. (* p,0.05, PM vs. PBS, n$4/group) Wild-
type and IL-6
2/2 mice were treated with urban PM (200 mg/mouse) or PBS and BAL fluid was obtained 24 hours later for measurement of (C) total
protein (D) cell count and (E) differential cell count. (*p,0.05, PM vs. PBS, n=8/group).
doi:10.1371/journal.pone.0018525.g004
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we observed a reduction in the PT, PTT, bleeding time and an
increase in plasma TAT in vehicle treated mice 24 hours after the
administration of PM (Figure 5G–J). The administration of
etanercept did not prevent the PM-induced reduction in bleeding
time, PT or PTT or increase in plasma TAT (Figure 5G–J).
Discussion
We found that PM-induced inflammation is sufficient to induce
a prothrombotic state and impair fibrinolysis in mice. Distinct
mechanisms underlie the activation of coagulation and the
inhibition of fibrinolysis as the activation of coagulation required
the generation of IL-6, whereas the increase in PAI-1 required
signaling through TNF-a independent of IL-6. In a standard and
physiologically relevant inhalational model of PM exposure, we
found evidence of IL-6-mediated gene transcription in the lung
and the development of an IL-6-dependent prothrombotic state.
In the same model, the administration of an inhibitor antibody
against TNF-a prevented the systemic increase in PAI-1. The
inhalation of PM was sufficient to increase expression of tissue
factor, a transcriptional target of IL-6, and the intratracheal
Figure 5. TNF-a but not IL-6 is required for urban PM-induced local and systemic release of PAI-1. Wild-type (IL-6
+/+) and IL-6
2/2 mice
were treated with PM (200 mg/mouse) or PBS and lung and white adipose tissues, BAL fluid and plasma were harvested 24 hours later. (A) Whole
lung PAI-1 mRNA, (B) BAL fluid PAI-1 antigen, (C) adipose tissue PAI-1 mRNA and (D) BAL fluid TNF-a levels were measured. Wild-type mice were
treated with either etanercept, a TNF-a inhibitor (10 mg/kg i.p.) or vehicle (saline) 3 days and on the day of exposure to PM (200 mg/mouse) or PBS
and BAL fluid, white adipose tissue and plasma were harvested or a bleeding time after tail vein cut performed 24 hours later. BAL fluid PAI-1 antigen
(E), white adipose tissue PAI-1 mRNA (F), bleeding time after tail vein cut (G), plasma prothrombin time (PT) (H), partial thromboplastin time (PTT) (I)
and plasma thrombin-antithrombin (TAT) complexes (J) were measured. (p,0.05, *PM vs. PBS, n$4/group).
doi:10.1371/journal.pone.0018525.g005
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intrapulmonary deposition of fibrin.
Healthy people and people with pre-existing coronary artery
disease exhibit a reduction in plasma tissue plasminogen activator
in the first 24 hours after exposure to PM, suggesting that PM
exposure might impair fibrinolysis. [4,15,26]. Fibrinolysis de-
scribes the degradation of fibrin by plasmin resulting in the
generation of fibrin degradation products. Two fibrinolytic
enzymes, urokinase-type plasminogen activator and tissue-type
plasminogen activator are primarily responsible for the activation
of plasmin from plasminogen [17]. Both of these enzymes are
inhibited by PAI-1. Elevated levels of circulating PAI-1 have been
identified as an independent risk factor for the development of
ischemic cardiovascular events [27,28] and have been associated
with obesity, insulin resistance, aging, stress, inflammation and
atherosclerosis [29]. We found that exposure to PM increases PAI-
1 levels in the lung and in the white adipose tissue, the major
source of circulating PAI-1 [18,30].
The PAI-I promoter contains several functional binding sites for
NF-kB [31], which is strongly activated by TNF-a [19] but lacks
binding sites for STAT3, the primary transcription factor activated
by IL-6 [32]. Consistent with these observations, we observed a
similar PM-induced increase in PAI-1 in IL-6
2/2 and wild-type
animals. Etanercept is a fusion protein combining the human TNF
receptor2withhumanIgGandhasbeenshowntoinhibitmurineas
well as human TNF-a signaling [33]. The administration of
etanercept prior to PM exposure prevented the increase in PAI-1
transcription in the white adipose tissue and the increase in BAL
PAI-1 induced by PM. Our results suggest that the inhibition of
fibrinolysis is not required for the PM-induced tendency toward
developing thrombosis as treatment with etanercept did not prevent
the PM-induced reduction in PT, PTT or bleeding time or the
increase in plasma TAT. While an increase in PAI-1 is often
presented as evidence of inhibited fibrinolysis, we did not directly
assessthebloodortissue fibrinolyticactivityafterPMexposure[29].
While our data do not address the source of TNF-a required for
the induction of PAI-1 expression in the white adipose tissue, we
previously reported that the intratracheal instillation of coarse PM
was associated with only very small increases in the plasma levels
of TNF-a [14]. Even this low level of TNF-a signaling, if
sustained, may be sufficient to stimulate the production of PAI-1
by adipocytes. Alternatively, some particles may gain access to the
circulation and induce a local inflammatory response in or near
the adipose tissue.
The risk of ischemic cardiovascular events in humans increases
with increasing exposure to PM [34,35,36]. While the mechanisms
by which PM increases acute cardiovascular events are not fully
understood, we and others have suggested that the consequences
of PM-induced lung inflammation on hemostasis play an
important role in this response [1,3,9,11,14,15,37,38]. Exposure
of humans to PM has been associated with increases in fibrinogen
levels, shortening of the prothrombin time and the development of
arterial (ischemic cardiovascular events) and venous (venous
thromboembolism) thrombosis [1,5,37]. We previously reported
that the intratracheal administration of coarse PM from
Dusseldorf, Germany caused a transient prothrombotic state,
which required the release of IL-6 from alveolar macrophages
[14,38]. Our current results extend these findings; we found that a
fine PM fraction collected from Washington DC administered
intratracheally and the inhalation of CAPs were both sufficient to
cause an IL-6-dependent prothrombotic state.
Investigators have observed increases in both IL-6 and its
transcriptional target C-reactive protein (expressed in humans but
not mice) in humans following PM exposure [10,11]. Our results
highlight the importance of IL-6 in the development of the PM-
induced prothrombotic state independent of other markers of
inflammation. Following the intratracheal administration of PM,
we found that the severity of the inflammatory response as
measured by BAL fluid cell count, BAL fluid protein and histology
were similar in wild-type and IL-6
2/2 mice, however, the increase
in TAT was not observed in the IL-6
2/2 animals. In mice exposed
to CAPs for 8 hours daily on 3 consecutive days, the increase in
IL-6 was small but was still sufficient to increase transcription of
the IL-6 target genes surfactant protein B and tissue factor and
increase the plasma levels of TAT [20,39]. The unique role of IL-6
in promoting thrombosis is well-described [39]. One mechanism,
supported by our current results, is the transcriptional upregula-
tion of tissue factor expression. Other important mechanisms
include increased hepatic synthesis of the pro-coagulant factors
fibrinogen, Factor VIII and vWF and reduced transcription of
inhibitors of thrombosis including Protein C and Antithrombin.
We previously reported that PM-treated animals exhibited
selective, IL-6 dependent increases in fibrinogen, FVIII and
vWF [14]. Investigators have not reported similar changes in
coagulation in response to elevations in other pro-inflammatory
cytokines [39].
We observed an IL-6-dependent increase in whole lung mRNA
encoding tissue factor following exposure to CAPs and after the
instillation of PM. We were only able to detect tissue factor protein
in the lung and increased levels of fibrin after the instillation of
relatively high doses of PM. While this may reflect the limited
sensitivity of the available assays to detect the differential
expression of these proteins in the lung, we cannot exclude the
possibility that the increase in lung tissue factor results from the
modest PM-induced lung injury that we have observed in the lungs
of animals following PM exposure [7]. Our results are in
agreement with those of Sun et al who observed an increase in
TF expression in atherosclerotic plaques in a murine model of
atherosclerosis after chronic exposure to CAPs [40]. Interestingly,
increased levels of PAI-1 have been observed in atherosclerotic
lesions and may be contribute to the development or progression
of the disease [41].
We conclude that the lung inflammation induced by the
inhalation of PM2.5 is sufficient to activate coagulation and inhibit
fibrinolysis in the lung and systemically. PM induced IL-6
generation was required for the increased in tissue factor and
fibrin in the lung and the systemic increase in TAT levels. By
contrast, PM-induced TNF-a generation was required for the
observed increase in PAI-1 but did not contribute to the PM-
induced reduction in PT, PTT or bleeding time. Both mechanisms
provide a link between exposure to PM and the observed increase
in ischemic cardiovascular events in human populations.
Materials and Methods
Particulate Matter
For intratracheal exposure experiments in mice, we used an
urban PM collected from ambient air in Washington, DC
(National Institute of Standards and Technology Standard
Reference Material, SRM 1649a). The characteristics of PM have
been previously described [21]. For inhalational exposure, we used
concentrated ambient PM2.5 (PM,2.5 mm) (CAPs) collected and
concentrated via the Versatile Aerosol Concentration Enrichment
System (VACES) [16].
Animals and intratracheal administration of PM
The animal protocol (ASP-2009-1041) was approved by the
Animal Care and Use Committee at Northwestern University. We
Particulate Matter Impairs Fibrinolysis
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+/+) and
IL-6 knockout mice (IL-6
2/2) (Jackson Laboratories, Bar Harbor,
Maine). We anesthetized the mice with isoflurane and intubated
them orally with a 20-gauge angiocath [7,14]. We instilled either
PM suspended in 50 ml of sterile PBS (vortexed prior to instillation)
or PBS (negative control). For some experiments, the administra-
tion of LPS (4 mg/kg, intratracheally) was used as a positive
control [7,14].
Exposure of mice to CAPs
We exposed mice to CAPs (concentrated from ambient air in
downtown Chicago with levels of traffic at ,106 of ambient
PM2.5 levels) for 8 hours per day (9 AM to 5 PM) for 3 days in one
of two identical chambers connected to the outflow of a PM2.5
concentrator (VACES) [16,42,43]. We exposed control mice to
filtered air in an identical chamber connected to the VACES in
which a HEPA filter was placed on the inlet valve. We estimated
ambient PM2.5 concentrations as the mean of reported values from
the 3 EPA monitoring locations closest to our location. Particle
counts in the chamber were measured with a TSI 3775 particle
counter (Shoreview, MN) and used to determine the enrichment in
the chamber compared with the ambient air as previously
described [16,42,43].
Collection of lung, bronchoalveolar lavage fluid and
plasma
We removed the lungs and heart en bloc, inflated the lungs to
15 cm of H2O with 4% paraformaldehyde, embedded in paraffin
and sectioned them (5-mm). We have previously described the
procedures for harvesting of the lungs for immunoblotting and
RNA isolation and the collection of BAL fluid and plasma [14,44].
Histology and immunohistochemistry
The severity of lung injury was scored by examining
hematoxylin and eosin stained lung sections using a previously
described 5-point lung injury scoring system (perivascular and
peribronchial inflammation, hyaline membranes, alveolar and
interstitial infiltrates, and alveolar hemorrhage) [25,45].
Quantification of lysed fibrin
We measured lysed, soluble fibrin in the BAL fluid as previously
described [24]. We divided the BAL fluid into two equal aliquots;
the first was snap frozen to determine pre-incubation D-dimer
levels and the second was incubated with plasmin (0.32 AU/mL)
at 37uC for 4 hours [24]. We measured D-dimer levels (ELISA,
Diagnostica-Stago, Parsippany, NJ) in both aliquots and reported
lysed fibrin levels as the difference between pre- and post-plasmin
digestion D-dimer levels.
Measurement of bleeding time, prothrombin time (PT),
partial thromboplastin time (PTT), thrombin-
antithrombin (TAT) complex and plasminogen activator
inhibitor-1 (PAI-1) antigen
We measured PT, PTT, and plasma TAT levels as previously
described [14] and PAI-1 antigen levels in BAL fluid by ELISA
(Innovative Research, Novi, MI).
Immunoblotting for tissue factor (TF)
For immunoblotting, we probed 10 mg of protein from mouse
lung homogenates with a rabbit TF antibody (American
Diagnostica, Stamford, CT, 1 mg/ml). We visualized the protein
bands were using chemiluminescence and analyzed the resulting
images with Image J software. We probed the same blots with and
antibody against glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (loading control).
Quantitative real-time reverse transcription PCR (qRT-PCR)
measurement of RNA
We isolated total RNA using a commercially available system
(TRIzol, Invitrogen, Carlsbad, CA) from mouse lungs [44] and
performed qRT-PCR reactions using IQ SYBR Green superscript
with the primers listed below, analyzed on a Biorad IQ5 Real-
Time PCR Detection System. We employed the Pfaffl method to
analyze the normalized data as previously described [44]. PAI-1:
(forward 59-ACGCCTGGTGCTGGTGAATGC-39, reverse 59-
ACGGTGCTGCCATCAGACTTGTG-39), 18s: (forward: 59-
GGGTCGGGAGTGGGTAATT39, reverse 59-GAGAGGGAG-
CCTGAGAAAC-39) [46] and TF: (forward 59-CTACTGTTT
CAGTGTTCAAGCAGTGA-39, reverse 59-CAGTGC AATA-
TAGCATTTGCAGTAGC-39) [47].
Cell culture
A549 cells were obtained from the American Type Culture
Collection (ATCC, Manassas, VA) and maintained in Dulbecco’s
modified Eagle’s medium supplemented with L-glutamine
(0.3 mg/ml), nonessential amino acids, penicillin (100 U/ml),
streptomycin (200 mg/ml), and 10% fetal bovine serum (GIBCO,
Grand Island, NY). For each experiment, we used a seeding
density of 3.0610
5 cells/ml/well plated onto six-well plates
(Costar, Cambridge, MA). The cells were grown to confluence
over 24 h in a humidified 95% air/5% CO2 incubator at 37uC.
Statistical analysis
We report all data as mean 6 SEM. We subjected all data to a
one-way ANOVA analysis. When ANOVA indicated a significant
difference, we explored individual difference with the Student’s t-
test using Bonferroni correction for multiple comparisons (Prism 4,
Graphpad, San Diego, CA). Statistical significance was defined as
p,0.05.
Supporting Information
Figure S1 The intratracheal instillation of urban PM is
associated with a dose-dependent increase in lung IL-6
and plasma thrombin antithrombin complexes. Wild-type
mice were treated with increasing doses of urban PM or vehicle
(PBS) and BAL fluid and plasma were obtained 24 hours later.
Mice treated with LPS (4 mg/kg, intratracheally) were used as a
positive control. BAL fluid levels of IL-6 (A) and plasma levels of
thrombin antithrombin (TAT) complexes (B) were measured.
Each bar represents 4 or more animals; p,0.05, *PM compared
with PBS control, {LPS vs. PM 200 mg/mouse.
(TIF)
Figure S2 Exposure of lung epithelial cells to PM results
in increased expression of tissue factor mRNA and
protein and increased deposition of fibrin in the lung.
Lung epithelial cells (A549 cells) were treated with PBS or PM and
processed, lysed 12 hours and 24 hours, respectively to measure
levels of tissue factor mRNA (A) and protein (B). Protein is
normalized to tubulin measurement by densitometry (ImageJ
software); mRNA is normalized to 18S mRNA. Results are
representative of three separate experiments. *p,0.05 for
comparison between PM and PBS treatment groups. Mice were
treated with increasing doses of urban PM or vehicle (PBS). LPS
(4 mg/kg, intratracheally) was used as a positive control. OCT
and snap frozen lung sections were obtained 24 hours after
Particulate Matter Impairs Fibrinolysis
PLoS ONE | www.plosone.org 7 April 2011 | Volume 6 | Issue 4 | e18525treatment and stained using an antibody that recognizes both
fibrin and fibrinogen (C). Representative sections (4006) from 4
mice are shown.
(TIF)
Figure S3 The intratracheal instillation of urban PM is
associated with a dose-dependent increase in lung injury
and inflammation. Mice were treated with increasing doses of
urban PM or vehicle (PBS) and lung tissue, BAL fluid and plasma
were obtained 24 hours later. Mice treated with LPS (4 mg/kg,
intratracheally) were used as a positive control. Representative
lung sections from 3 mice treated with the indicated does (1006
and 4006) are shown (A). The stained lung sections were scored
using a previously described lung injury severity scoring system
[25] for the presence of (1) perivascular and peribronchial
inflammation (Inflammation), (2) hyaline membranes, (3) alveolar
infiltrates, (4) interstitial infiltrates and (5) alveolar hemorrhage (B).
BAL fluid was obtained for measurement of total protein (C) and
cell count (D). Each bar represents 4 or more animals; p,0.05,
*PM compared with PBS control, {LPS vs. PM 200 mg/mouse).
(TIF)
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